Oxford Immunotec Global PLC
New Monthly Series Spotlights What 100 Physicians Find to be Critical Needs in Their Battle Against COVID-19
New Monthly Series Spotlights What 100 Physicians Find to be Critical Needs in Their Battle Against COVID-19
The first survey results reveal physicians seek new diagnostic tools and insights to improve COVID-19 management and patient outcomes
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, announces the launch of
100 Physicians Find, a monthly survey that takes the pulse of one hundred medical professionals on the front lines of the COVID-19 pandemic about their perspectives, experiences and needs in the face of this global health crisis.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Oxford Immunotec’s T-SPOT® Discovery SARS-CoV-2 Test is Used to Measure the Efficacy of .
Oxford Immunotec Global PLCJanuary 13, 2021 GMT
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, announce the start of a collaboration with Valneva. The Company will perform T cell testing on participants receiving Valneva’s inactivated whole-virus COVID-19 vaccine candidate (VLA2001) with the research use only T-SPOT
Discovery SARS-CoV-2 test. The VLA2001-201 study is a randomized Phase I/II clinical study designed to evaluate the safety, tolerability and immunogenicity of an inactivated SARS-CoV-2 virus vaccine candidate in healthy subjects, the first study of its kind performed in Europe.
PerkinElmer buying UK diagnostics firm for $591 million
By Anissa Gardizy Globe Staff,Updated January 7, 2021, 4:03 p.m.
Email to a Friend
A PerkinElmer automated workstation, which is used in labs around the world. On Thursday, the company announced it would acquire Oxford Immunotec, which makes tests for diagnosing tuberculosis.-
PerkinElmer announced on Thursday it will acquire UK diagnostics company Oxford Immunotec in a deal worth $591 million.
The Waltham-based firm makes lab equipment and software for health care companies, drug companies, and food manufacturers, and the move will help the company expand its infectious-disease testing arm. Oxford Immunotecâs anchor product is a test kit used for diagnosing tuberculosis.
PerkinElmer, Inc.: PerkinElmer to Acquire Oxford Immunotec Global PLC
Transaction expected to be completed in the first half of 2021
PerkinElmer, Inc. (NYSE: PKI) (
Oxford Immunotec or the
Company ) are pleased to announce they have reached an agreement on terms under which PerkinElmer will acquire Oxford Immunotec (the
Acquisition ). It is intended that the Acquisition will be implemented by means of a U.K. High Court of Justice-sanctioned scheme of arrangement under Part 26 of the U.K. Companies Act 2006 between Oxford Immunotec and its shareholders (the
Scheme
Under the terms of the Acquisition, Oxford Immunotec shareholders will be entitled to receive USD 22.00 in cash for each outstanding ordinary share (